ArticleCureus2026
Definitive Radiotherapy in Serous Carcinoma of Unknown Primary With Isolated Nodal Disease: A Case Review.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-grade serous carcinoma (HGSC) is an aggressive malignancy that may arise from the endometrium, ovary, fallopian tube, or peritoneum, but in rare cases, the primary site remains unknown. Isolated nodal presentation is particularly uncommon, and in such cases, it is inferred to be metastasis. Serous carcinoma of unknown primary (SCUP) lacks management guidelines, with treatment often extrapolated from other gynecologic cancers. We describe the case of a woman with isolated inguinal and pelvic nodal SCUP who achieved durable disease control with definitive radiotherapy after progression on endocrine therapy. An 88-year-old woman presented with a large left inguinal mass. Biopsy demonstrated HGSC of Müllerian origin. She was initiated on tamoxifen 20 mg twice a day; however, after seven months, the inguinal mass enlarged, and CA-125 levels increased from 2,691 U/mL to 4,191 U/mL. Given her frailty and the morbidity associated with resecting nodes with clinical extracapsular extension, the patient underwent definitive external beam radiotherapy (55 Gy/25 fractions to involved nodes; 45 Gy/25 fractions to the ipsilateral groin and hemipelvis). Six months after radiotherapy, CT showed a reduction of the inguinal mass and pelvic sidewall lymph node, with CA-125 levels declining to 19 U/mL. The patient has remained without disease progression by imaging and CA-125 for 30 months following completion of radiotherapy. This case describes an uncommon presentation of HGSC of Mullerian origin with isolated inguinal nodes in the absence of identifiable uterine, adnexal, or peritoneal primary. In the absence of established guidelines, it demonstrates the feasibility of definitive radiotherapy in achieving durable disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.